Literature DB >> 3005486

Protection of weanling hamsters from experimental infection with wild-type parainfluenza virus type 3 (para 3) by cold-adapted mutants of para 3.

F K Crookshanks-Newman, R B Belshe.   

Abstract

Parainfluenza virus type 3 (para 3) was adapted to replicate at 20 degrees C, a nonpermissive temperature for wild-type (wt) para 3. Serial passage at 20 degrees C resulted in the generation of cold-adapted (ca) and temperature-sensitive (ts) mutants. These mutant viruses have been characterized both in vitro and in vivo [Belshe and Hissom (1982): Journal of Medical Virology 10:235-242; Crookshanks and Belshe (1984): Journal of Medical Virology 13:243-249]. We now report the evaluation of three mutants (clone 1150, passaged 12 times in the cold [cp12], clone 1146, passaged 18 times in the cold [cp18], and clone 1328, passaged 45 times in the cold [cp45]) for their ability to protect hamsters from infection by wild-type para 3. Ether-anesthetized male syrian hamsters were intranasally vaccinated with either wt para 3 (clone 127) or one of the ca para 3 mutants and on day 28 post-vaccination; each animal was intranasally challenged with 10(5.0) pfu of wt para 3. On days 1, 2, 3, and 4 post-challenge, 4 to 13 hamsters from each group were sacrificed, and the quantity of para 3 in the nasal turbinates and lungs was determined. Wt virus induced protection from challenge. cp12, cp18, and cp45 reduced the peak titer of wt replication in the lungs by greater than 100-fold, tenfold, and tenfold, respectively. The duration of virus replication was shortened also by intranasal vaccination with the mutants. These data give evidence of an inverse relationship between the degree of protection induced by vaccination with cold-adapted mutants and the number of passages of the virus in the cold.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3005486     DOI: 10.1002/jmv.1890180205

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  12 in total

1.  Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees.

Authors:  M L Clements; R B Belshe; J King; F Newman; T U Westblom; E L Tierney; W T London; B R Murphy
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

2.  Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.

Authors:  A C Schmidt; J M McAuliffe; B R Murphy; P L Collins
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

3.  Characterization of a live, attenuated human parainfluenza type 3 virus candidate vaccine strain.

Authors:  R Ray; K Meyer; F K Newman; R B Belshe
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

4.  The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young children.

Authors:  Ruth A Karron; Roberta Casey; Bhagvanji Thumar; Sonja Surman; Brian R Murphy; Peter L Collins; Alexander C Schmidt
Journal:  Pediatr Infect Dis J       Date:  2011-10       Impact factor: 2.129

5.  Antibody responses of humans and nonhuman primates to individual antigenic sites of the hemagglutinin-neuraminidase and fusion glycoproteins after primary infection or reinfection with parainfluenza type 3 virus.

Authors:  K L van Wyke Coelingh; C C Winter; E L Tierney; S L Hall; W T London; H W Kim; R M Chanock; B R Murphy
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

Review 6.  Current approaches to the development of vaccines effective against parainfluenza viruses.

Authors:  B R Murphy
Journal:  Bull World Health Organ       Date:  1988       Impact factor: 9.408

7.  Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine.

Authors:  M H Skiadopoulos; S Surman; J M Tatem; M Paschalis; S L Wu; S A Udem; A P Durbin; P L Collins; B R Murphy
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

8.  Temperature-sensitive phenotype of the human parainfluenza virus type 3 candidate vaccine strain (cp45) correlates with a defect in the L gene.

Authors:  R Ray; M S Galinski; B R Heminway; K Meyer; F K Newman; R B Belshe
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

9.  Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in children.

Authors:  R B Belshe; R A Karron; F K Newman; E L Anderson; S L Nugent; M Steinhoff; M L Clements; M H Wilson; S L Hall; E L Tierney
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

Review 10.  Parainfluenza viruses.

Authors:  Kelly J Henrickson
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.